skip to Main Content

Welcome to Responsum Health

Responsum Health is harnessing the promise of the Internet to better inform and engage patients with chronic conditions. Join us!

Get In Touch

Email: info@responsumhealth.com
Phone: +1 (949) 264 2277
Headquarters Office: Washington, DC
Operations Office: Irvine, CA

Our Location

Get to know a new clinical trial for IPF

This clinical research study for idiopathic pulmonary fibrosis may benefit you

What are the benefits of participating in clinical trials?

Young Male Doctor Smiles At Older Male Patient With IPF

Medical professionals use clinical trials to test new investigational medications, procedures, and treatments. The goal of this study is to understand how well a new experimental medication works in conjunction with your current treatment plan for lung function and IPF.

If you are selected, you’ll receive study medication, study-related medical care, and reimbursement for study-relatd expenses. Some participants will receive the trial drug, while others will receive a placebo.

As with all clinical trials, there is no guaranteed benefit or outcome to the experimental treatment that is under investigation. If you’re interested in clinical trial participation, you should consult with your doctor beforehand to determine whether a clinical trial is right for you.

You may be eligible for this clinical trial if

You are 40 years of age or older and can come to a study center for routine visits
You have been diagnosed with IPF within the last five years
You haven't been diagnosed with an immunosuppressive condition, such as HIV
You have not yet had a lung transplant

If your conditions vary from those above, you may still qualify.
Find out if you’re eligible.

Additional trial information

How does the study work?

This clinical study program is made up of two identical designed studies, which are intended to confirm each other’s results. The studies consist of an up to four-week screening period (to see whether patients qualify for participation), a treatment period of at least 52 weeks, and a follow-up period of four weeks. At least 13 visits to the site are foreseen in these periods. Participant health will be monitored throughout the studies.

What will happen during the study?

During the study, participants are requested to do the following:

  • Take the study medication as instructed by the study doctor
  • Attend all scheduled study visits
  • Answer questions about their health
  • Complete lung function tests
  • Provide urine and blood samples at study visits
  • Follow all instructions from the study staff

How long will the study last?

The study will continue until the last participant has reached week 52 in the study. There will then be a follow-up period of four weeks.

Looking for more information on pulmonary fibrosis?
Check out Responsum for PF!

Back To Top